Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

BCI Minerals Limited

ABN

21 120 646 924

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Performance rights.

- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- Principal of the 3 terms ⁺securities (e.g. if options, exercise price and expiry date; if ⁺securities, partly paid the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

11,000,000 performance rights.

Performance rights issued pursuant to the Company's Performance Rights Plan approved by shareholders at the 27 November 2019 AGM subject to certain performance conditions. For details of the terms and conditions of the Company's Performance Rights Plan, please refer to the Notice of AGM released to ASX on 25 October 2019.

⁺ See chapter 19 for defined terms.

4	 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	No – new class of unquoted security. On vesting of the performance rights, the shares issued will rank equally with existing quoted fully paid ordinary shares.
5	Issue price or consideration	Nil consideration – issued pursuant to the terms and conditions of the BCI Performance Rights Plan.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued to MD Alwyn Vorster (refer Resolution 7 of the 27 November 2019 Notice of AGM) and senior staff members pursuant to the Performance Rights Plan approved by shareholders at the Company's AGM held on 27 November 2019.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the</i> ⁺ <i>securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	27 November 2019
6с	Number of ⁺ securities issued without security holder approval under rule 7.1	Nil
6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	Nil

+ See chapter 19 for defined terms.

- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 5,000,000 pe the AGM 1 (Resolution 7
- 6f Number of *securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable)

5,000,000 performance rights – approved at						
the	AGM	held	on	27	November	2019
(Resolution 7).						

6,000,000 performance rights - ASX Listing Rule 7.2 exemption 13 (Performance Rights Plan was approved at the AGM held on 27 November 2019).

N/A

N/A

Listing Rule 7.1 - 59,839,336.

Listing Rule 7.1A - 39,892,891.

18 December 2019.

Number	+Class
398,928,910	Fully paid ordinary shares (ASX: BCI)

Appendix 3B Page 3

		Number	+Class
not qu	er and +class of all +securities noted on ASX (including the rities in section 2 if applicable)	11,000,000	Performance Rights

10	Dividend policy (in the case of a trust, distribution policy) on the	BCI Minerals may pay dividends to ordinary shareholders as the Directors
	\cdot 1 \cdot 1/ \cdot	resolve.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non- renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their	N/A
	entitlements are to be dealt with. Cross reference: rule 7.7.	
	cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

32

- 20 Names of any underwriters
- 21 Amount of any underwriting fee N/A or commission
- 22 Names of any brokers to the N/A issue
- 23 Fee or commission payable to] the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if N/A applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?

N/A				

How do security holders dispose N/A

- See chapter 19 for defined terms.	⊦ See	chapter	19 for	defined	terms.
-------------------------------------	-------	---------	--------	---------	--------

N/A

A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

	of their entitlements (except by sale through a broker)?						
33	⁺ Issue date	N/A					
Part 3 - Quotation of securities							
You nee	You need only complete this section if you are applying for quotation of securities						
34	34 Type of ⁺ securities (<i>tick one</i>)						

+Securities described in Part 1

(a)

(b)	All other ⁺ securities
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- 36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
- 37 A copy of any trust deed for the additional ⁺securities

Entities that have ticked box 34(b)

38 Number of *securities for which *quotation is sought
39 *Class of *securities for which quotation is sought
N/A

If the additional ⁺securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation N/A now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another ⁺security, clearly identify that other ⁺security)

- f Number +Class
- 42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in clause 38)

	Number	+Class
1	N/A	N/A
ζ		
2		

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

⁺ See chapter 19 for defined terms.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

APHente .

Sign here:

......Date: 20 December 2019 (Director/Company secretary)

Print name:

Susan Hunter

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figue capacity is calculated	ire from which the placement			
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	398,928,910			
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot 				
 other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil			
" A "	398,928,910			

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"В"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	59,839,336
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil
Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	Nil
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15	59,839,336
Note: number must be same as shown in Step 2	
Subtract "C"	Nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	59,839,336
	[Note: this is the remaining placement capacity under rule 7.1]

Part 2

from which the placement	
98,928,910	
Step 2: Calculate 10% of "A"	
10	
ote: this value cannot be changed	
9,892,891	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
il	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10	39,892,891
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	39,892,891
	Note: this is the remaining placement capacity under rule 7.1A